Camp4 Therapeutics Corp

For the period ended Dec 31, 2024. Filed Mar 27, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 27, 2025

CAMP$4.33-7.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated balance sheets as of December 31, 202 and

Consolidated Balance Sheets

(In thousands, except share and per share amounts)

	December 31,
Assets	2024	2023
Current assets:
Cash and cash equivalents	$64,039	$38,380
Prepaid expenses and other current assets	2,344	1,633
Total current assets	66,383	40,013
Restricted cash	1,624	1,624
Property and equipment, net	3,858	4,797
Operating lease right-of-use assets	6,015	7,764
Finance lease right-of-use assets	427	748
Total assets	$78,307	$54,946
Liabilities, Convertible Preferred Stock and Stockholders’ Equity (Deficit)
Current liabilities:
Accounts payable	$1,210	$1,042
Accrued expenses and other current liabilities	4,833	3,302
Deferred revenue	385	—
Operating lease liabilities, current portion	2,994	2,704
Finance lease liabilities, current portion	91	354
Financing liability, current portion	85	405
Total current liabilities	9,598	7,807
Operating lease liabilities, net of current portion	5,493	8,487
Finance lease liabilities, net of current portion	70	148
Financing liability, net of current portion	—	85
Other long-term liabilities	2	2
Total liabilities	15,163	16,529
Commitments and contingencies (Note 7)
Convertible preferred stock, $0.0001 par value per share; 25,000,000 and 149,673,284 shares authorized; no and 130,648,426 shares issued and outstanding; liquidation value of zero and $162,885 as of December 31, 2024 and 2023, respectively	—	162,147
Stockholders’ equity (deficit):
Common stock, $0.0001 par value per share; 175,000,000 and 210,000,000 shares authorized; 20,161,072 and 1,026,057 shares issued, 20,145,129 and 460,704 shares outstanding as of December 31, 2024 and 2023, respectively	2	1
Additional paid-in capital	274,895	36,231
Accumulated deficit	(211,753)	(159,962)
Total stockholders’ equity (deficit)	63,144	(123,730)
Total liabilities, convertible preferred stock and stockholders’ equity (deficit)	$78,307	$54,946

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.